MINNEAPOLIS, April 15, 2014 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) announced that a three judge panel of the U.S. Court of Appeals for the Federal Circuit today vacated the preliminary injunction that was previously issued by the District Court for the District of Minnesota effective January 13, 2014 against Boston Scientific's Guidezilla guide extension catheter. In its one paragraph opinion vacating the injunction, the Court noted that a preliminary injunction is a "drastic and extraordinary remedy that is not to be routinely granted" and "at this stage of the case the record is too incomplete . . . to warrant the grant of a preliminary injunction."
The Court's ruling on the preliminary injunction does not affect the underlying patent litigation, which is currently scheduled to be ready for trial on or after March 2015 in the District Court for the District of Minnesota.
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of more than 80 products in three categories: catheter products, hemostat products and vein products. Vascular Solutions delivers its products to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2013 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, lack of sustained profitability, exposure to intellectual property claims, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, doing business in international markets, the availability of third party reimbursement, and actions by the FDA. The District Court grant of preliminary injunction may be stayed or overturned on appeal, and the granting of a preliminary injunction is not a determination of the ultimate merits of the litigation, which will be determined by the presentation of evidence at trial or in future dispositive motions.
For further information, connect to www.vasc.com.